Spark Biomedical Archives - Medical Design Sourcing

Could minimally invasive neuromod tackle the opioid epidemic?

The Sparrow therapy system. [Image from Spark Biomedical] Officials at Spark Biomedical and AcuityMD think their partnership could accelerate the commercialization of Spark’s potentially game-changing platform.

Spark Biomedical develops a topical, minimally invasive medical device for alleviating opioid withdrawal symptoms. AcuityMD has a platform for helping medical device companies accelerate commercial access to their products.

Together, they seek to provide a pathway to life-restoring sobriety for millions suffering from opioid addiction. Last month, Spark and AcuityMD announced a partnership to accelerate the expansion of the former’s technology. The FDA-approved Sparrow therapy system represents a drug-free tool for helping treat opioid use disorder. It sends mild electrical impulses to the brain to help alleviate withdrawal symptoms.

AcuityMD’s data-driven commercial platform supports this expansion effort. It helps

“We saw an op…

Could minimally invasive neuromod tackle the opioid epidemic?

The Sparrow therapy system. [Image from Spark Biomedical]

Officials at Spark Biomedical and AcuityMD think their partnership could accelerate the commercialization of Spark’s potentially game-changing platform.

Spark Biomedical develops a topical, minimally invasive medical device for alleviating opioid withdrawal symptoms. AcuityMD has a platform for helping medical device companies accelerate commercial access to their products.

Together, they seek to provide a pathway to life-restoring sobriety for millions suffering from opioid addiction. Last month, Spark and AcuityMD announced a partnership to accelerate the expansion of the former’s technology. The FDA-approved Sparrow therapy system represents a drug-free tool for helping treat opioid use disorder. It sends mild electrical impulses to the brain to help alleviate withdrawal symptoms.

AcuityMD’s data-driven commercial platform suppo…

Battelle, Spark Biomedical partner on opioid use disorder detection, treatment

Battelle announced today that it entered into a collaborative agreement with Spark Biomedical to jointly run a pilot clinical study.

Through the joint study, the two companies aim to advance the remote detection and treatment of opioid use disorder (OUD) using wearable biosensors.

According to a news release, the study’s primary objective is to collect physiological data from the biosensors for patients experiencing opioid withdrawal symptoms, cravings and addiction-related physiological stressors using the Battelle NeuroHub system. Once data is acquired, the team will develop an artificial intelligence (AI) algorithm to detect withdrawal using objective physiological biomarkers.

Once the study is completed, Spark and Battelle intend to use the resulting AI algorithm to develop a new, more objective physiological assessment tool for opioid withdrawal measurement, as well as to develop AI and machine learning algorithms for understanding mental heal…